WO2001046443A3 - Proteases - Google Patents

Proteases Download PDF

Info

Publication number
WO2001046443A3
WO2001046443A3 PCT/US2000/034811 US0034811W WO0146443A3 WO 2001046443 A3 WO2001046443 A3 WO 2001046443A3 US 0034811 W US0034811 W US 0034811W WO 0146443 A3 WO0146443 A3 WO 0146443A3
Authority
WO
WIPO (PCT)
Prior art keywords
prts
provides
proteases
polynucleotides
agonists
Prior art date
Application number
PCT/US2000/034811
Other languages
French (fr)
Other versions
WO2001046443A2 (en
Inventor
Junming Yang
Mariah R Baughn
Neil Burford
Janice Au-Young
Dyung Aina M Lu
Roopa Reddy
Henry Yue
Danniel B Nguyen
Y Tom Tang
Monique G Yao
Preeti Lal
Original Assignee
Incyte Genomics Inc
Junming Yang
Mariah R Baughn
Neil Burford
Janice Au-Young
Dyung Aina M Lu
Roopa Reddy
Henry Yue
Danniel B Nguyen
Y Tom Tang
Monique G Yao
Preeti Lal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Junming Yang, Mariah R Baughn, Neil Burford, Janice Au-Young, Dyung Aina M Lu, Roopa Reddy, Henry Yue, Danniel B Nguyen, Y Tom Tang, Monique G Yao, Preeti Lal filed Critical Incyte Genomics Inc
Priority to JP2001546939A priority Critical patent/JP2004500812A/en
Priority to CA002394789A priority patent/CA2394789A1/en
Priority to AU22857/01A priority patent/AU2285701A/en
Priority to EP00986665A priority patent/EP1240335A2/en
Publication of WO2001046443A2 publication Critical patent/WO2001046443A2/en
Publication of WO2001046443A3 publication Critical patent/WO2001046443A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides human proteases (PRTS) and polynucleotides which identify and encode PRTS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PRTS.
PCT/US2000/034811 1999-12-23 2000-12-19 Proteases WO2001046443A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001546939A JP2004500812A (en) 1999-12-23 2000-12-19 Protease
CA002394789A CA2394789A1 (en) 1999-12-23 2000-12-19 Proteases
AU22857/01A AU2285701A (en) 1999-12-23 2000-12-19 Proteases
EP00986665A EP1240335A2 (en) 1999-12-23 2000-12-19 Proteases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US17205599P 1999-12-23 1999-12-23
US60/172,055 1999-12-23
US17733400P 2000-01-21 2000-01-21
US60/177,334 2000-01-21
US17888400P 2000-01-28 2000-01-28
US60/178,884 2000-01-28
US17990300P 2000-02-02 2000-02-02
US60/179,903 2000-02-02

Publications (2)

Publication Number Publication Date
WO2001046443A2 WO2001046443A2 (en) 2001-06-28
WO2001046443A3 true WO2001046443A3 (en) 2002-07-11

Family

ID=27496993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034811 WO2001046443A2 (en) 1999-12-23 2000-12-19 Proteases

Country Status (5)

Country Link
EP (1) EP1240335A2 (en)
JP (1) JP2004500812A (en)
AU (1) AU2285701A (en)
CA (1) CA2394789A1 (en)
WO (1) WO2001046443A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020724A1 (en) * 1998-06-16 2007-01-25 Ruben Steven M 94 human secreted proteins
US20020037513A1 (en) * 2000-03-24 2002-03-28 Rosana Kapeller-Libermann 33338, a novel human ubiquitin hydrolase-like molecule and uses thereof
WO2002008394A2 (en) * 2000-07-14 2002-01-31 Millenium Pharmaceuticals, Inc. 23430, a novel human ubiquitin hydrolase family member and uses therefor
AU2002225811A1 (en) 2000-11-30 2002-06-11 Millennium Pharmaceuticals, Inc. Methods of using 18903 to treat pain and pain-related disorders
WO2005075666A2 (en) * 2004-02-04 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with puromycin sensitive aminopeptidase npepps (npepps)
CA2590751A1 (en) 2004-12-13 2006-06-22 Roy Rabindranauth Sooknanan Polynucleotides and polypeptide sequences involved in the process of bone remodeling

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046289A1 (en) * 1998-03-12 1999-09-16 Human Genome Sciences, Inc. 31 human secreted proteins
WO2000078934A2 (en) * 1999-06-22 2000-12-28 School Of Pharmacy, University Of London Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease
WO2000079267A2 (en) * 1999-06-22 2000-12-28 School Of Pharmacy, University Of London Use of hte ubiquitin specific protease usp25 in the treatment, prophylaxis and diagnosis of cancer
WO2001021654A2 (en) * 1999-09-24 2001-03-29 Rigel Pharmaceuticals, Inc. Syk kinase-associated cell cycle proteins, compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046289A1 (en) * 1998-03-12 1999-09-16 Human Genome Sciences, Inc. 31 human secreted proteins
WO2000078934A2 (en) * 1999-06-22 2000-12-28 School Of Pharmacy, University Of London Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease
WO2000079267A2 (en) * 1999-06-22 2000-12-28 School Of Pharmacy, University Of London Use of hte ubiquitin specific protease usp25 in the treatment, prophylaxis and diagnosis of cancer
WO2001021654A2 (en) * 1999-09-24 2001-03-29 Rigel Pharmaceuticals, Inc. Syk kinase-associated cell cycle proteins, compositions and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 18 April 1997 (1997-04-18), ADAMS MD ET AL: "EST178661 Colon carcinoma (HCC) cell line Homo sapiens cDNA", XP002176713 *
DATABASE EMBL 23 June 1997 (1997-06-23), HILLIER L ET AL: "Homo sapiens cDNA clone", XP002176711 *
DATABASE EMBL 24 June 1997 (1997-06-24), NATIONAL CANCER INSTITUTE, CANCER GEMONE ANATOMY PROJECT (CGAP): "Homo sapiens cDNA clone similar to ubiqutin carboxyl-terminal hydrolase 2", XP002176712 *
GROET J ET AL: "NARROWING OF THE REGIONS OF ALLELIC LOSS IN 21Q11-21 IN SQUAMOUS NON-SMALL CELL LUNG CARCINOMA AND CLONING OF A NOVEL UBIQUITIN-SPECIFIC PROTEASE GENE FROM THE DELETED SEGMENT", GENES, CHROMOSOMES & CANCER, XX, XX, vol. 27, no. 2, February 2000 (2000-02-01), pages 153 - 161, XP000943091 *
VALERO REBECA ET AL: "USP25, a novel gene encoding a deubiquitinating enzyme, is located in the gene-poor region 21q11.2", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 62, no. 3, 15 December 1999 (1999-12-15), pages 395 - 405, XP002153277, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
EP1240335A2 (en) 2002-09-18
CA2394789A1 (en) 2001-06-28
JP2004500812A (en) 2004-01-15
AU2285701A (en) 2001-07-03
WO2001046443A2 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
WO2001098468A3 (en) Proteases
WO2003052075A3 (en) Enzymes
WO2002008396A3 (en) Human proteases
WO2002063005A3 (en) Lipid-associated molecules
WO2001046397A3 (en) Human kinases
WO2001072777A3 (en) Human transcription factors
WO2002038744A3 (en) Proteases
WO2003042357A3 (en) Enzymes
WO2001071004A3 (en) Proteases
WO2001096546A3 (en) Protein phosphatases
WO2002026950A3 (en) Transferases
WO2001032888A3 (en) Human transferase molecules
WO2000042201A3 (en) Human peptidases
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2002010363A3 (en) Protein phosphatases
WO2002020736A3 (en) Proteases
WO2001046443A3 (en) Proteases
WO2002024924A3 (en) Protein phosphatases
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2002026998A3 (en) Hydrolases
WO2002064795A3 (en) Putative human enzymes
WO2004003162A3 (en) Enzymes
WO2001092527A3 (en) Regulators of apoptosis
WO2001083775A3 (en) Proteases
WO2003072729A3 (en) Enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2394789

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10168425

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 546939

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000986665

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000986665

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000986665

Country of ref document: EP